A Food and Drug Administration project to promote diversity in clinical studies of cancer treatments was removed from the ...
6d
In a bombshell announcement made last week, the Food and Drug Administration (FDA) said it will ban the use of FD&C Red No. 3 ...
The FDA expanded the approval of trastuzumab deruxtecan for treatment of breast cancer.The new indication applies to use of ...
The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer ...
Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval | The FDA has cleared AstraZeneca and Daiichi Sankyo's ...
Northwell Health partnered with Stacker to explore how a new Pap smear alternative may help prevent deaths from cervical ...
After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bisepcifics ...
A panel discussion during the JPMorgan conference earlier this month examined where oncology drug development is headed, driven in part by advances in diagnostic testing.
The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast ...
The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.
Armando, a 71-year-old with an active lifestyle, was midway through a round of golf when a strange sensation crept into his ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback